オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - dobutamine hydrochloride, quantity: 14 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium metabisulfite - adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefazolin sodium, quantity: 2096 mg (equivalent: cefazolin, qty 2000 mg) - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms: respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present. genitourinary tract infections due to e. coli, p. mirabilis, and klebsiella sp. and some strains of enterobacter and enterococci. skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resisant) and group a beta-haemolytic streptococci and other strains of streptococci. bone and joint infections due to staph. aureus. septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), e. coli, p. mirabilis, and klebsiella sp. endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. note: appropriate culture and susceptibility studies should be preformed to determine susceptibility of the causative organism to cephazolin.

シンガポール - 英語 - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 0.75 mg/ml - eptifibatide 0.75 mg/ml

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

viatris limited - eptifibatide 0.75 mg/ml (75 mg in 100 ml) - solution for infusion - 0.75 mg/ml - active: eptifibatide 0.75 mg/ml (75 mg in 100 ml) excipient: citric acid monohydrate sodium hydroxide water for injection - indicated for patients undergoing non-urgent, percutaneous coronary intervention (pci) with coronary stenting for the reduction of death, myocardial infarction, urgent revascularisation and the need for acute antithrombotic rescue therapy. indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction. indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is intended for use with aspirin, heparin or clopidigrel.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - eptifibatide, quantity: 0.75 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; citric acid monohydrate - integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials). indications as at 29 november 2001: integrilin is indicated for patients undergoing nonurgent percutaneous coronary intervention with intracoronary stenting (see clinical trials). integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - eptifibatide, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium hydroxide - integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials). indications as at 29 november 2001: integrilin is indicated for patients undergoing nonurgent percutaneous coronary intervention with intracoronary stenting (see clinical trials). integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials).

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection usp and other antibacterial drugs, ceftriaxone for injection usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused by streptococcus pneumo

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefazolin sodium, quantity: 2198 mg - injection, powder for - excipient ingredients: - treatment of the following serious infections due to susceptible organisms.. respiratory tract infections due to strep. pneumoniae, klebsiella sp., h. influenzae, staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci. injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present.. genitourinary tract infections due to e. coli, p. mirabilis, klebsiella sp. and some strains of enterobacter and enterococci.. skin and skin structure infections due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci and other strains of streptococci.. bone and joint infections due to staph. aureus.. septicaemia due to strep. pneumoniae, staph. aureus (penicillin sensitive and penicillin resistant), p. mirabilis, e. coli and klebsiella sp.. endocarditis due to staph. aureus (penicillin sensitive and penicillin resistant) and group a beta-haemolytic streptococci.. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cephazolin.